Pediatric Focus Target pediatric dosing and safety as a core differentiator to position partnerships and co-development opportunities with larger pharma players seeking pediatric solutions.

Regulatory Track Capitalize on history of FDA approved enalapril oral solution to pursue expansion of pediatric formulations and related cardiovascular indications through licensing or collaborative development with stakeholders in pediatrics and cardiology.

Acquisition History Leverage exposure from the CutisPharma acquisition and Azurity branding to approach distributors and contract manufacturers for channel expansion, manufacturing scale partnerships, and synergistic product portfolios.

Market Position Position as a specialized, small-to-mid-size player with proven capability in safe pediatric medications to pursue co-marketing, access programs, and government/funding opportunities targeting child health therapies.

Growth Signals Align outreach with fundraising and growth signals reflected in revenue scale and recent product launches to engage investors, potential strategic buyers, and collaboration talks around pipeline expansion and international market entry.